DYAI
Price
$0.91
Change
-$0.02 (-2.15%)
Updated
Aug 28 closing price
Capitalization
32.84M
68 days until earnings call
MDGL
Price
$434.58
Change
-$2.59 (-0.59%)
Updated
Aug 29, 01:42 PM (EDT)
Capitalization
9.74B
62 days until earnings call
Interact to see
Advertisement

DYAI vs MDGL

Header iconDYAI vs MDGL Comparison
Open Charts DYAI vs MDGLBanner chart's image
Dyadic International
Price$0.91
Change-$0.02 (-2.15%)
Volume$16.45K
Capitalization32.84M
Madrigal Pharmaceuticals
Price$434.58
Change-$2.59 (-0.59%)
Volume$115
Capitalization9.74B
DYAI vs MDGL Comparison Chart in %
Loading...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYAI vs. MDGL commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYAI is a Buy and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (DYAI: $0.91 vs. MDGL: $437.17)
Brand notoriety: DYAI and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYAI: 10% vs. MDGL: 74%
Market capitalization -- DYAI: $32.84M vs. MDGL: $9.74B
DYAI [@Biotechnology] is valued at $32.84M. MDGL’s [@Biotechnology] market capitalization is $9.74B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYAI’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • DYAI’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYAI’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • DYAI’s TA Score: 5 bullish, 5 bearish.
  • MDGL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than DYAI.

Price Growth

DYAI (@Biotechnology) experienced а +16.18% price change this week, while MDGL (@Biotechnology) price change was +7.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.14%. For the same industry, the average monthly price growth was +15.09%, and the average quarterly price growth was +29.14%.

Reported Earning Dates

DYAI is expected to report earnings on Nov 05, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-1.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.74B) has a higher market cap than DYAI($32.8M). MDGL YTD gains are higher at: 41.676 vs. DYAI (-48.149). DYAI has higher annual earnings (EBITDA): -5.09M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. DYAI (4.98M). DYAI has less debt than MDGL: DYAI (5.06M) vs MDGL (124M). MDGL has higher revenues than DYAI: MDGL (516M) vs DYAI (3.42M).
DYAIMDGLDYAI / MDGL
Capitalization32.8M9.74B0%
EBITDA-5.09M-266.74M2%
Gain YTD-48.14941.676-116%
P/E RatioN/AN/A-
Revenue3.42M516M1%
Total Cash4.98M797M1%
Total Debt5.06M124M4%
FUNDAMENTALS RATINGS
DYAI vs MDGL: Fundamental Ratings
DYAI
MDGL
OUTLOOK RATING
1..100
428
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
10026
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8837
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (67) in the Pharmaceuticals Other industry is in the same range as DYAI (93) in the Biotechnology industry. This means that MDGL’s stock grew similarly to DYAI’s over the last 12 months.

MDGL's Profit vs Risk Rating (26) in the Pharmaceuticals Other industry is significantly better than the same rating for DYAI (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than DYAI’s over the last 12 months.

MDGL's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as DYAI (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to DYAI’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for DYAI (88) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than DYAI’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as DYAI (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to DYAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYAIMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 15 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
THAR6.051.09
+21.98%
Tharimmune Inc.
RDNT71.790.50
+0.70%
RadNet
WLFC150.00-1.04
-0.69%
Willis Lease Finance Corp
BMY46.88-0.75
-1.57%
Bristol-Myers Squibb Co
PBYI4.97-0.13
-2.55%
Puma Biotechnology

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-2.53%
MDGL - DYAI
29%
Poorly correlated
+2.85%
FATE - DYAI
28%
Poorly correlated
-3.57%
TAOX - DYAI
27%
Poorly correlated
-5.42%
QSI - DYAI
25%
Poorly correlated
-0.86%
AUPH - DYAI
24%
Poorly correlated
-0.25%
More